Literature DB >> 9468230

Inflammatory bowel disease and smoking--a review.

G A Thomas1, J Rhodes, J T Green.   

Abstract

The relationship between smoking and inflammatory bowel disease is a curious but well-established one. It is negatively associated with ulcerative colitis but positively associated with Crohn's disease. It also has opposite influences on the clinical course of the two conditions with possible beneficial effect in ulcerative colitis and detrimental effect in Crohn's disease. The diametrically "opposite" relationship of smoking status with the two conditions has been the subject of much interest in the hope that it may reveal pathogenic mechanisms responsible for the two conditions and possibly offer the key to alternative therapeutic options. Nicotine may be the principal agent in smoking responsible for the association; trials have shown it to be of some benefit in ulcerative colitis, but further research is required to establish its therapeutic role and possible mechanisms of action. In this article, we review the historical, clinical, and therapeutic aspects of the association between smoking and inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9468230     DOI: 10.1111/j.1572-0241.1998.00144.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  21 in total

Review 1.  Nicotine treatment for ulcerative colitis.

Authors:  M Guslandi
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

Review 2.  Infliximab treatment for Crohn's disease.

Authors:  C A Conroy; R Cattell
Journal:  Postgrad Med J       Date:  2001-07       Impact factor: 2.401

3.  Environmental factors associated with Crohn's disease in India.

Authors:  Srinivasan Pugazhendhi; Manoj Kumar Sahu; Venkataraman Subramanian; Anna Pulimood; Balakrishnan S Ramakrishna
Journal:  Indian J Gastroenterol       Date:  2011-12-13

4.  (E)-metanicotine hemigalactarate (TC-2403-12) inhibits IL-8 production in cells of the inflamed mucosa.

Authors:  Tanja Spoettl; Christine Paetzel; Hans Herfarth; Merouane Bencherif; Juergen Schoelmerich; Roland Greinwald; Gregory J Gatto; Gerhard Rogler
Journal:  Int J Colorectal Dis       Date:  2006-05-20       Impact factor: 2.571

5.  Long-term durability of Crohn's disease treatment with infliximab.

Authors:  Stephen J Rudolph; David I Weinberg; Robert P McCabe
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

Review 6.  Etiopathogenesis of inflammatory bowel diseases.

Authors:  Silvio Danese; Claudio Fiocchi
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

7.  The role of bacteria in the pathogenesis of inflammatory bowel disease.

Authors:  Melissa Friswell; Barry Campbell; Jonathan Rhodes
Journal:  Gut Liver       Date:  2010-09-24       Impact factor: 4.519

8.  MEFV gene mutations and its impact on the clinical course in ulcerative colitis patients.

Authors:  Beytullah Yıldırım; Candan Tuncer; Derya Kan; Bilge Tunc; Mehmet Derya Demirag; E Ferda Percın; Seminur Haznedaroglu; Hakan Alagozlu
Journal:  Rheumatol Int       Date:  2010-03-12       Impact factor: 2.631

9.  Survey of inflammatory bowel diseases in India.

Authors:  Govind K Makharia; Balakrishnan S Ramakrishna; Philip Abraham; Gourdas Choudhuri; Sri Prakash Misra; Vineet Ahuja; Shobna J Bhatia; Deepak K Bhasin; Sunil Dadhich; Gopal K Dhali; Devendra C Desai; Uday C Ghoshal; B D Goswami; Sanjeev K Issar; Ajay K Jain; Venkataraman Jayanthi; Goundappa Loganathan; C Ganesh Pai; Amarender S Puri; Surinder S Rana; Gautam Ray; Shivaram P Singh; Ajit Sood
Journal:  Indian J Gastroenterol       Date:  2012-10-17

10.  Passive smoking and inflammatory bowel disease: a meta-analysis.

Authors:  Deborah T Jones; Mark T Osterman; Meenakshi Bewtra; James D Lewis
Journal:  Am J Gastroenterol       Date:  2008-09       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.